Trending menu:
Seattle Genetics has commenced dosing in a Phase III clinical trial of its tucatinib drug in combination with Kadcyla (ado-trastuzumab emtansine) in HER2-positive (HER2+) breast cancer patients.
Alder BioPharmaceuticals has dosed the first participant in a Phase I clinical trial being conducted to assess its investigational monoclonal antibody (mAb) ALD1910 for the prevention of migraine.
Clinical trials technology provider VirTrial has formed an alliance to enable virtual clinical trials at Pratia clinical research centres in Europe.
US antiviral drugmaker Gilead Sciences and Belgo-Dutch biotech Galapagos have announced week 52 data from the Phase III FINCH 1 and 3 trials of rheumatoid arthritis (RA) candidate filgotinib.
Biopharmaceutical firm Dermira has commenced a Phase III programme comprising two identical trials of lebrikizumab for the treatment of moderate-to-severe atopic dermatitis.
Biopharmaceutical services provider Parexel has entered a multi-year collaboration with healthcare data services firm Datavant to link real-world data across clinical trials.
Clinical-stage biopharmaceutical company Anavex Life Sciences has initiated a long-term extension study for patients with early Alzheimer’s disease (AD) and treated with ANAVEX2-73 (blarcamesine).
Debiopharm has started enrolling patients in its CATRIPCA Phase I clinical trial evaluating Debio 1143 in combination with Merck’s Keytruda for the treatment of cancer.
Biopharmaceutical company ONL Therapeutics has commenced a Phase I clinical trial to assess its investigational drug, ONL1204, for the treatment of macula-off rhegmatogenous retinal detachment (RRD).
Bavarian Nordic has started a Phase I clinical trial to assess its vaccine candidate MVA-BN WEV for prophylaxis against equine encephalitis virus.
